Merck Voluntarily Withdraws Ifinatamab Deruxtecan License Application for Small Cell Lung Cancer

RegulatoryrejectedIfinatamab DeruxtecanNegative

AI Analysis

Summary

Merck has voluntarily withdrawn its license application for Ifinatamab Deruxtecan in small cell lung cancer, representing a regulatory setback for the antibody-drug conjugate program.

Outcome Details

Voluntary withdrawal of license application

Importance:7/10

Sentiment:

-0.80

regulatory_withdrawalsmall_cell_lung_cancerantibody_drug_conjugate

Related Companies

$MRK

Read the original article

Published by yahoo_finance on September 25, 2026 8:56 PM

Read Original